Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats

Journal of Pharmaceutical and Biomedical Analysis

Volumn 61, Issue , 2012, Pages 57-63

  Qian, Shuai ^a   Wo, Siu Kwan ^a   Zuo, Zhong ^a  

^a Prince of Wales Hospital   (Hong Kong)

Author keywords

Brain disposition; Fluorescence; Hydroxytacrine; Pharmacokinetics; Tacrine

Indexed keywords

2 HYDROXYTACRINE; 4 HYDROXYTACRINE; ACETIC ACID ETHYL ESTER; DRUG METABOLITE; FORMIC ACID; TACRINE; TRIETHYLAMINE; UNCLASSIFIED DRUG; VELNACRINE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; BRAIN REGION; COLUMN CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ISOLATION; ELUTION; FLUORESCENCE; HYDROXYLATION; IN VIVO STUDY; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; QUALITY CONTROL; RAT; STANDARD; TISSUE HOMOGENATE;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MALE; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, FLUORESCENCE; TACRINE;

EID: 84856096395     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.11.025     Document Type: Article

References (29)

1. Friedlander A.H., Norman D.C., Mahler M.E., Norman K.M., Yagiela J.A. Alzheimer's disease: psychopathology, medical management and dental implications. J. Am. Dent. Assoc. 2006, 137:1240-1251.
2. Li W., Mak M., Jiang H., Wang Q., Pang Y., Chen K., Han Y. Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics 2009, 6:187-201.
3. Wilkinson D.G., Francis P.T., Schwam E., Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004, 21:453-478.
4. Jogani V.V., Shah P.J., Mishra P., Mishra A.K., Misra A.R. Nose-to-brain delivery of tacrine. J. Pharm. Pharmacol. 2007, 59:1199-1205.
5. Summers W.K. Tacrine (THA, Cognex (R)). J. Alzheimers Dis. 2000, 2:85-93.
6. Jasti B.R., Marasanapalle V.P., Crison J.R., Ma J.W., Li X.L. Investigation of some factors contributing to negative food effects. Biopharm. Drug Dispos. 2009, 30:71-80.
7. Madden S., Spaldin V., Park B.K. Clinical pharmacokinetics of tacrine. Clin. Pharmacokinet. 1995, 28:449-457.
8. Madden S., Woolf T.F., Pool W.F., Park B.K. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem. Pharmacol. 1993, 46:13-20.
9. Woolf T.F., Pool W.F., Bjorge S.M., Chang T., Goel O.P., Purchase C.F., Schroeder M.C., Kunze K.L., Trager W.F. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab. Dispos. 1993, 21:874-882.
10. Madden S., Spaldin V., Hayes R.N., Woolf T.F., Pool W.F., Park B.K. Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 1995, 25:103-116.
11. Hsu R.S., Shutske G.M., Dileo E.M., Chesson S.M., Linville A.R., Allen R.C. Identification of the urinary metabolites of tacrine in the rat. Drug Metab. Dispos. 1990, 18:779-783.
12. Pool W.F., Reily M.D., Bjorge S.M., Woolf T.F. Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons. Drug Metab. Dispos. 1997, 25:590-597.
13. Birks J., Wilcock G.G. Velnacrine for Alzheimer's disease. Cochrane Database Syst. Rev. 2004, CD004748.
14. Murphy M.F., Hardiman S.T., Nash R.J., Huff F.J., Demkovich J.J., Dobson C., Knappe U.E. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease. Ann. N.Y. Acad. Sci. 1991, 640:253-262.
15. Patocka J., Jun D., Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr. Drug Metab. 2008, 9:332-335.
16. Domingo J.L. Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents. J. Alzheimers Dis. 2006, 10:331-341.
17. Wong Y.C., Zuo Z. Intranasal delivery-modification of drug metabolism and brain disposition. Pharm. Res. 2010, 27:1208-1223.
18. Jogani V.V., Shah P.J., Mishra P., Mishra A.K., Misra A.R. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis. Assoc. Disord. 2008, 22:116-124.
19. Hsu R.S., DiLeo E.M., Chesson S.M. High-performance liquid chromatography for the determination of tacrine and its metabolites in plasma. J. Chromatogr. 1990, 530:170-176.
20. Hansen L.L., Larsen J.T., Brosen K. Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and fluorescence detection. J. Chromatogr. B: Biomed. Sci. Appl. 1998, 712:183-191.
21. Aymard G., Cayre-Castel M., Fernandez C., Lacomblez L., Diquet B. High-performance liquid chromatography with ultraviolet and fluorimetric detection for the simultaneous determination of tacrine, nimodipine, and their respective metabolites in the plasma of patients with Alzheimer disease. Ther. Drug Monit. 1998, 20:422-429.
22. Haughey D.B., McNaney C.A., Collis M.S., Brown R.R., Siedlik P.H., Balogh L., Klockowski P.M. Simultaneous determination of tacrine and 1-hydroxy-, 2-hydroxy-, and 4-hydroxytacrine in human plasma by high-performance liquid chromatography with fluorescence detection. J. Pharm. Sci. 1994, 83:1582-1585.
23. Bao D., Thanabal V., Pool W.F. Determination of tacrine metabolites in microsomal incubate by high performance liquid chromatography-nuclear magnetic resonance/mass spectrometry with a column trapping system. J. Pharm. Biomed. Anal. 2002, 28:23-30.
24. Cloos K.C., Hondo T. Rapid determination of tacrine and other drug metabolites in microsomal incubate by newly developed targeting algorithm on UHPLC/TOFMS. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:4171-4174.
25. Marques L.A., Kool J., de Kanter F., Lingeman H., Niessen W., Irth H. Production and on-line acetylcholinesterase bioactivity profiling of chemical and biological degradation products of tacrine. J. Pharm. Biomed. Anal. 2010, 53:609-616.
26. US Food and Drug Administration Guidance for Industry, Bioanalytical Method Validation 2001, Centre for Drug Evaluation and Research (CDER), Rockville.
27. McNally W.P., Pool W.F., Sinz M.W., Dehart P., Ortwine D.F., Huang C.C., Chang T., Woolf T.F. Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue. Drug Metab. Dispos. 1996, 24:628-633.
28. Hooper W.D., Pool W.F., Woolf T.F., Gal J. Stereoselective hydroxylation of tacrine in rats and humans. Drug Metab. Dispos. 1994, 22:719-724.
29. Yu H., Li W.M., Kan K.K., Ho J.M., Carlier P.R., Pang Y.P., Gu Z.M., Zhong Z., Chan K., Wang Y.T., Han Y.F. The physicochemical properties and the in vivo AChE inhibition of two potential anti-Alzheimer agents, bis(12)-hupyridone and bis(7)-tacrine. J. Pharm. Biomed. Anal. 2008, 46:75-81.